CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF
Provided are a CLDN18.2-targeting antibody or an antigen-binding fragment thereof, a preparation method therefor, and the use thereof. The antibody comprises a light chain variable region and/or a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | JHENG, Ming-Jin ZHANG, Wei WANG, Jieli |
| description | Provided are a CLDN18.2-targeting antibody or an antigen-binding fragment thereof, a preparation method therefor, and the use thereof. The antibody comprises a light chain variable region and/or a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. Compared with the prior art, the antibody has significant advantages in terms of binding affinity, ADCC, CDC, inhibitory effects on growth, endocytic activity, etc.
L'invention concerne un anticorps ciblant CLDN18.2 ou un fragment se liant à l'antigène de celui-ci, un procédé de préparation correspondant et son utilisation. L'anticorps comprend une région variable de chaîne légère et/ou une région variable de chaîne lourde, et la région variable de chaîne lourde comprend HCDR1, HCDR2 et HCDR3, et la région variable de chaîne légère comprend LCDR1, LCDR2 et LCDR3. Par comparaison avec l'état de la technique, l'anticorps présente des avantages signific |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021063336A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021063336A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021063336A13</originalsourceid><addsrcrecordid>eNrjZPB09nHxM7TQM9INcQxydw3x9HNXcPQL8XTyd4nUUQgIcg1wDHIM8fT3U_B1DfHwd1EI8XANcnXzD9IBKnNRCA12hYj4u_EwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDI0MDM2NjYzNHQ2PiVAEAq6AtlA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF</title><source>esp@cenet</source><creator>JHENG, Ming-Jin ; ZHANG, Wei ; WANG, Jieli</creator><creatorcontrib>JHENG, Ming-Jin ; ZHANG, Wei ; WANG, Jieli</creatorcontrib><description>Provided are a CLDN18.2-targeting antibody or an antigen-binding fragment thereof, a preparation method therefor, and the use thereof. The antibody comprises a light chain variable region and/or a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. Compared with the prior art, the antibody has significant advantages in terms of binding affinity, ADCC, CDC, inhibitory effects on growth, endocytic activity, etc.
L'invention concerne un anticorps ciblant CLDN18.2 ou un fragment se liant à l'antigène de celui-ci, un procédé de préparation correspondant et son utilisation. L'anticorps comprend une région variable de chaîne légère et/ou une région variable de chaîne lourde, et la région variable de chaîne lourde comprend HCDR1, HCDR2 et HCDR3, et la région variable de chaîne légère comprend LCDR1, LCDR2 et LCDR3. Par comparaison avec l'état de la technique, l'anticorps présente des avantages signific</description><language>chi ; eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210408&DB=EPODOC&CC=WO&NR=2021063336A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210408&DB=EPODOC&CC=WO&NR=2021063336A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JHENG, Ming-Jin</creatorcontrib><creatorcontrib>ZHANG, Wei</creatorcontrib><creatorcontrib>WANG, Jieli</creatorcontrib><title>CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF</title><description>Provided are a CLDN18.2-targeting antibody or an antigen-binding fragment thereof, a preparation method therefor, and the use thereof. The antibody comprises a light chain variable region and/or a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. Compared with the prior art, the antibody has significant advantages in terms of binding affinity, ADCC, CDC, inhibitory effects on growth, endocytic activity, etc.
L'invention concerne un anticorps ciblant CLDN18.2 ou un fragment se liant à l'antigène de celui-ci, un procédé de préparation correspondant et son utilisation. L'anticorps comprend une région variable de chaîne légère et/ou une région variable de chaîne lourde, et la région variable de chaîne lourde comprend HCDR1, HCDR2 et HCDR3, et la région variable de chaîne légère comprend LCDR1, LCDR2 et LCDR3. Par comparaison avec l'état de la technique, l'anticorps présente des avantages signific</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPB09nHxM7TQM9INcQxydw3x9HNXcPQL8XTyd4nUUQgIcg1wDHIM8fT3U_B1DfHwd1EI8XANcnXzD9IBKnNRCA12hYj4u_EwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDI0MDM2NjYzNHQ2PiVAEAq6AtlA</recordid><startdate>20210408</startdate><enddate>20210408</enddate><creator>JHENG, Ming-Jin</creator><creator>ZHANG, Wei</creator><creator>WANG, Jieli</creator><scope>EVB</scope></search><sort><creationdate>20210408</creationdate><title>CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF</title><author>JHENG, Ming-Jin ; ZHANG, Wei ; WANG, Jieli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021063336A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>JHENG, Ming-Jin</creatorcontrib><creatorcontrib>ZHANG, Wei</creatorcontrib><creatorcontrib>WANG, Jieli</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JHENG, Ming-Jin</au><au>ZHANG, Wei</au><au>WANG, Jieli</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF</title><date>2021-04-08</date><risdate>2021</risdate><abstract>Provided are a CLDN18.2-targeting antibody or an antigen-binding fragment thereof, a preparation method therefor, and the use thereof. The antibody comprises a light chain variable region and/or a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. Compared with the prior art, the antibody has significant advantages in terms of binding affinity, ADCC, CDC, inhibitory effects on growth, endocytic activity, etc.
L'invention concerne un anticorps ciblant CLDN18.2 ou un fragment se liant à l'antigène de celui-ci, un procédé de préparation correspondant et son utilisation. L'anticorps comprend une région variable de chaîne légère et/ou une région variable de chaîne lourde, et la région variable de chaîne lourde comprend HCDR1, HCDR2 et HCDR3, et la région variable de chaîne légère comprend LCDR1, LCDR2 et LCDR3. Par comparaison avec l'état de la technique, l'anticorps présente des avantages signific</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng ; fre |
| recordid | cdi_epo_espacenet_WO2021063336A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING |
| title | CLDN18.2-TARGETING ANTIBODY, PREPARATION METHOD THEREFOR, AND USE THEREOF |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A39%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JHENG,%20Ming-Jin&rft.date=2021-04-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021063336A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |